- Market Capitalization, $K 1,054,935
- Shares Outstanding, K 103,021
- Annual Sales, $ 150 K
- Annual Income, $ -59,350 K
- 60-Month Beta 2.02
- Price/Sales 7,016.57
- Price/Cash Flow N/A
- Price/Book 3.86
|Period||Period Low||Period High||Performance|
| || |
-1.79 (-14.88%)since 03/12/21
| || |
-4.73 (-31.60%)since 01/14/21
| || |
+5.34 (+108.98%)since 04/14/20
Investors in Trillium Therapeutics Inc saw new options begin trading today, for the December 17th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the...
, /PRNewswire/ -- The cancer treatment market is one of the biggest segments of the biotechnology industry. According to the National Cancer Institute, roughly 1.8 million people were diagnosed with...
Toronto, Ontario--(Newsfile Corp. - March 30, 2021) - (CSE: MSET) (OTCQB: MSSTF) (FSE: 9DF)("" or the ""), a drug discovery and development company focused on developing next generation psilocybin and...
Investors in Trillium Therapeutics Inc saw new options begin trading this week, for the November 19th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is...
Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results, including...
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ISR, TRIL, PLUG, BXRX, and ASLN.
Vancouver, British Columbia--(Newsfile Corp. - February 16, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) ("" or the ""), a biotechnology company focused on developing psychedelic...
, /PRNewswire/ -- The growing prevalence of cancer all over the globe is a major obstacle to overcome. In 2020, an estimated 1,806,590 new cases of cancer were diagnosed in alone and 606,520 people...
, /PRNewswire/ -- With the onset of a world health crisis, our seniors are at a greater risk than they were a decade ago. In addition, the growing senior population has tripled in size over the past...
--New investments include companies focused on Oncology, Rare Disease, and Inflammation & Immunology
|3rd Resistance Point||11.10|
|2nd Resistance Point||10.89|
|1st Resistance Point||10.56|
|1st Support Level||10.02|
|2nd Support Level||9.81|
|3rd Support Level||9.48|